193698-89-4Relevant academic research and scientific papers
Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-α-amino acid competitive NMDA antagonists of the AP-6 type
Baudy,Fletcher III,Yardley,Zaleska,Bramlett,Tasse,Kowal,Katz,Moyer,Abou-Gharbia
, p. 1516 - 1529 (2007/10/03)
A series of 2-amino-(phosphonoalkyl)-1H-benzimidazole-2-alkanoic acids was synthesized and evaluated for NMDA receptor affinity using a [3H]CPP binding assay. Functional antagonism of the NMDA receptor complex was evaluated in vitro using a stimulated [3H]TCP binding assay and in vivo by employing an NMDA-induced seizure model. Several compounds of the AP-6 type demonstrated potent and selective NMDA antagonistic activity both in vitro and in vivo. In particular, [R(-)]-2-amino-3-(5-chloro-1-phosphonomethyl-1H-benzoimidazol-2-yl)-propionic acid (1) displayed an IC50 value of 7.1 nM in the [3H]CPP binding assay and an ED50 value of 0.13 mg/kg (ip) in the NMDA lethality model. Compound 1, when administered intravenously as a single bolus dose of 3 mg/kg following permanent occlusion of the middle cerebral artery in the rat, reduced the volume of infarcted brain tissue by 45%. These results support a promising therapeutic potential for compound 1 as a neuroprotective agent.
Benzimidazole phosphono-amino acids
-
, (2008/06/13)
This invention provides a process for the preparation of a compound of formula I STR1 wherein R1 and R2 are each, independently, hydrogen, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, methanesulfonylamino, acetylamino, halo, cyano, nitro, or when taken together R1 and R2 represent a methylenedioxy or ethylenedioxy moiety; or a pharmaceutically acceptable salt thereof.
